|
1）Moorhead JF, Chan MK, El-Nahas M, et al. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982; 2: 1309-11
|
|
|
|
2）Faraggiana T, Churg J. Renal lipidoses: a review. Hum Pathol. 1987; 18: 661-79
|
|
|
|
|
3）日本腎臓学会，編．CKD診療ガイド2012．東京：東京医学社；2012. p. 76-8
|
|
|
|
|
|
4）Nitta K. Clinical assessment and management of dyslipidemia in patients with chronic kidney disease. Clin Exp Nephrol. 2012; 16: 522-9
|
|
|
|
|
5）Dalrymple LS, Kaysen GA. The effect of lipoproteins on the development and progression of renal disease. Am J Nephrol. 2008; 28: 723-31
|
|
|
|
|
|
6）Tsimihodimos V, Dounousi E, Siamopoulos KC. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol. 2008; 28: 958-73
|
|
|
|
|
|
7）Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001; 59: 260-9
|
|
|
|
|
|
8）Sandhu S, Wiebe N, Fried LF, et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006; 17: 2006-16
|
|
|
|
|
|
9）Shepherd J, Kastelein JJ, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007; 2: 1131-9
|
|
|
|
|
|
10）Oikawa S, Suzuki N, Sakuma E, et al. Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy. Am J Kidney Dis. 1991; 18: 553-8
|
|
|
|
|
|
11）Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis. 2006; 47: 199-211
|
|
|
|
|
|
12）斉藤喬雄．リポ蛋白糸球体症の病態．日内会誌．2006; 95: 1838-44
|
|
|
|
|
13）Saito T, Sato H, Kudo K, et al. Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. Am J Kidney Dis. 1989; 13: 148-53
|
|
|
|
|
|
14）Watanabe Y, Ozaki I, Yoshida F, et al. A case of nephrotic syndrome with glomerular lipoprotein deposition with capillary ballooning and mesangiolysis. Nephron. 1989; 51: 265-70
|
|
|
|
|
|
15）斉藤喬雄．リポ蛋白糸球体症．腎と透析．2012; 72増刊: 429-32
|
|
|
|
|
|
16）Oikawa S, Matsunaga A, Saito T, et al. Apolipoprotein E Sendai (arginine 145->proline): a new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol. 1997; 8: 820-3
|
|
|
|
|
|
17）Matsunaga A, Sasaki J, Komatsu T, et al. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int. 1999; 56: 421-7
|
|
|
|
|
|
18）Foster K, Matsunaga A, Matalon R, et al. A rare cause of posttransplantation nephrotic syndrome. Am J Kidney Dis. 2005; 45: 1132-8
|
|
|
|
|
|
19）Rovin BH, Roncone D, McKinley A, et al. APOE Kyoto mutation in European Americans with lipoprotein glomerulopathy. N Engl J Med. 2007; 357: 2522-4
|
|
|
|
|
|
20）Han J, Pan Y, Chen Y, et al. Common apolipoprotein E gene mutations contribute to lipoprotein glomerulopathy in China. Nephron Clin Pract. 2010; 114: c260-7
|
|
|
|
|
|
21）斉藤喬雄，小河原悟，伊藤建二，他．脂質代謝異常症．日内会誌．2011; 100: 1220-6
|
|
|
|
|
|
22）Sam R, Wu H, Yue L, et al. Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding. Am J Kidney Dis. 2006; 47: 539-48
|
|
|
|
|
|
23）Luo B, Huang F, Liu Q, et al. Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy. Am J Nephrol. 2008; 28: 347-53
|
|
|
|
|
|
24）Mitani A, Ishigami M, Watase K, et al. A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy. J Atheroscler Thromb. 2011; 18: 531-5
|
|
|
|
|
|
25）Tokura T, Itano S, Kobayashi S, et al. A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy. J Atheroscler Thromb. 2011; 18: 536-41
|
|
|
|
|
|
26）Hoffmann M, Scharnagl H, Panagiotou E, et al. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy. J Am Soc Nephrol. 2001; 12: 524-30
|
|
|
|
|
|
27）Ishigaki Y, Oikawa S, Suzuki T, et al. Virus-mediated transduction of apolipoprotein E (ApoE)-Sendai develops lipoprotein glomerulopathy in ApoE-deficient mice. J Biol Chem. 2000; 275: 31269-73
|
|
|
|
|
|
28）Wen M, Segerer S, Dantas M, et al. Renal injury in apolipoprotein E-deficient mice. Lab Invest. 2002; 82: 999-1006
|
|
|
|
|
|
29）Yamamoto S, Yancey PG, Zuo Y. Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Arterioscler Thromb Vasc Biol. 2011; 31: 2856-64
|
|
|
|
|
|
30）Ishimura A, Watanabe M, Nakashima H, et al. Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice. Clin Exp Nephrol. 2009; 13(5): 430-7
|
|
|
|
|
|
31）Kanamaru Y, Nakao A, Shirato I, et al. Chronic graft-versus-host autoimmune disease in Fc receptor gamma chain-deficient mice results in lipoprotein glomerulopathy. J Am Soc Nephrol. 2002; 13: 1527-33
|
|
|
|
|
|
32）Miyahara Y, Nishimura S, Watanabe M, et al. Scavenger receptor expressions in the kidneys of mice with lipoprotein glomerulopathy. Clin Exp Nephrol. 2012; 16: 115-21
|
|
|
|
|
|
33）Calvo D, Gomez-Coronado D, Suarez Y, et al. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. J Lipid Res. 1998; 39: 777-88
|
|
|
|
|
|
34）Febbraio M, Podrez EA, Smith JD, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000; 105: 1049-56
|
|
|
|
|
|
35）Yamamoto N, Ikeda H, Tandon NN, et al. A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: Naka- platelets lack detectable GPIV (CD36). Blood. 1990; 76: 1698-703
|
|
|
|
|
|
36）Ito K, Nakashima H, Watanabe M, et al. Macrophage impairment produced by Fc receptor gamma deficiency plays a principal role in the development of lipoprotein glomerulopathy in concert with apoE abnormalities. Nephrol Dial Transplant. [Epub ahead of print]
|
|
|
|
|
|
37）Ricardo SD, van Goor H, Diamond JR. Hypercholesterolemia and progressive kidney disease: the role of macrophages and macrophage-derived products. Contrib Nephrol. 1997; 120: 197-209
|
|
|
|
|
|
38）Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science. 1995; 267(5200): 1034-7
|
|
|
|
|
|
39）Linton MF, Gish R, Hubl ST, et al. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest. 1991; 88: 270-81
|
|
|
|
|
|
40）Basu SK, Brown MS, Ho YK, et al. Mouse macrophages synthesize and secrete a protein resembling apolipoprotein E. Proc Natl Acad Sci U S A. 1981; 78: 7545-9
|
|
|
|
|
|
41）Atkinson RD, Coenen KR, Plummer MR, et al. Macrophage-derived apolipoprotein E ameliorates dyslipidemia and atherosclerosis in obese apolipoprotein E-deficient mice. Am J Physiol Endocrinol Metab. 2008; 294: E284-90
|
|
|
|
|
|
42）Trusca VG, Fuior EV, Florea IC, et al. Macrophage-specific up-regulation of apolipoprotein E gene expression by STAT1 is achieved via long range genomic interactions. J Biol Chem. 2011; 286: 13891-904
|
|
|
|
|
|
43）Baitsch D, Bock HH, Engel T, et al. Apolipoprotein E induces antiinflammatory phenotype in macrophages. Arterioscler Thromb Vasc Biol. 2011; 31: 1160-8
|
|
|
|
|
|
44）Wang Y, Harris DCH. Macrophages in renal disease. J Am Soc Nephrol. 2011; 22: 21-7
|
|
|
|
|
|
45）Yamamoto S, Yancey PG, Zuo Y, et al. Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Arterioscler Thromb Vasc Biol. 2011; 31: 2856-64
|
|
|
|
|